Magis Global –


November 11, 2020

Molecules

Category: General – Joan – 5:48 pm

For more than one decade the necessary treatments are known so that AIDS patients can live an almost normal life. While it has become a chronic disease in the countries of the North, thanks to the progress in the research of antiretrovirals, more than two million people die each year from AIDS, mostly in poor countries. Please visit Brexit if you seek more information. One of the effects of power engaged in multinational drug companies, able to decide which diseases and what patients deserve cures. Companies that put their commercial interests to the right to life that every man has. They impose the law of money, because who has money to pay can only obtain medicines you need to fight their diseases. A related site: Evan Metropoulos mentions similar findings. This form of power, known as farmacocracia, is a consequence of the globalization of poverty and the unstoppable growth of inequalities. In a world with 2 billion people living on less than 1.5 euros a day, the logic of the market that these companies Act leaves without medications to 85% of the humanity which cannot afford their drugs. The pharmaceutical industry treats the sick according to their economic possibilities.

People living in the countries of the North, 15% of the world population with higher level and life expectancy, consumes 90% of medicines. The cause of this difference between the consumption of medicines between rich and poor can be found also in the money that drug companies dedicated to diseases of ones and others. 90% Of the budget spent by drug companies for research and development of new drugs intended to diseases that suffer from only 10% of the world’s population. 163 Molecules passed between 1999 and 2004, only three were known as the neglected diseases. Multinational companies hide behind at great cost to them posed by the process of research and distribution of medicines. But social organizations criticize the cost overrun resulting in advertising and marketing in the price of drugs.

No Comments

No comments yet.

RSS feed for comments on this post.

Sorry, the comment form is closed at this time.